Edwards Lifesciences (EW) announced that the U.S. District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission for an injunction blocking the company’s proposed acquisition of JenaValve Technology. As a result, Edwards will not acquire JenaValve. Edwards disagrees with the decision and believes that the acquisition would have been in the best interest of a large, growing and underserved group of patients. In light of this update, Edwards is revising its full-year 2026 adjusted EPS guidance to $2.90-$3.05 from earlier guidance of $2.80-$2.95. FY26 consensus $2.87.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences upgraded to Buy from Hold at TD Cowen
- Edwards Lifesciences price target raised to $108 from $104 at Goldman Sachs
- Becton Dickinson price target raised to $215 from $210 at Stifel
- Edwards Lifesciences price target raised to $105 from $100 at Stifel
- Edwards Lifesciences price target raised to $94 from $92 at Evercore ISI